Cloacibacillus evryensis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Cloacibacillus evryensis is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 7 gut microbiome compilation studies or metastudies. The DNA G+C content is 55.8%. Cloacibacillus evryensis is probably a common, although minor, coloniser of the gut. (Domingo2015; Ganesan2008)



  • This organism has been recovered from human faeces, and wastewater. Could be a possible pathogen in humans, but unknown at this stage. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Ganesan2008);
    Character Response
  • 🧂
  • Salt tolerance:
  • tolerates 0-0.7% salt;
  • pH
  • Acidity tolerance:
  • doesn't tolerate pH 4.2-5.9; tolerates pH 10; Grows optimally at pH 7.
  • 🌡
  • Temperature tolerance:
  • grows at 20℃; grows at 50℃; Grows optimally at 37℃.
  • ⥅
  • Substrates assimilated or utilised:
  • arginine; histidine; lysine; serine; tryptophan; Casamino acids;
    • SPECIAL FEATURES (Ganesan2008);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (major); butyrate; COâ‚‚; Hâ‚‚;
  • ✗
  • Metabolites not produced:
  • propionate; valerate;
  • ✗
  • Nitrate:
  • not reduced
  • ✗
  • Sulfate:
  • not reduced
  • ✗
  • Thiosulfate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Domingo2015); (Ganesan2008);
    Class Active Resistant
  • Penicillins:
  • ampicillin; meropenem; penicillin;
  • Cephalosporins:
  • cefoxitin;
  • Aminoglycosides:
  • kanamycin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;

  • Ganesan, A., Chaussonnerie, S., Tarrade, A., Dauga, C., Bouchez, T., Pelletier, E., Le Paslier, D., & Sghir, A. (2008). Cloacibacillus evryensis gen. nov., sp. nov., a novel asaccharolytic, mesophilic, amino-acid-degrading bacterium within the phylum “Synergistetes”, isolated from an anaerobic sludge digester. International Journal of Systematic and Evolutionary Microbiology, 58(Pt 9), 2003–2012.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Synergistetes Class:  Synergistia Order:  Synergistales Family:  Synergistaceae Genus:  Cloacibacillus Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces, and wastewater
    DNA G+C(%):  55.8
    Opt. T:  37℃
    Lower T(℃):  20(+)
    High T(℃):  50(+)
    NaCl 0.5-2%:  0-0.7(+)
    Opt. pH:  7
    pH 4.2-5.9:  4.2-5.9(neg)
    pH >8:  10(+)
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Ala:  w Arg:  + Asp:  w Cys:  w Glu:  w Gly:  w His:  + Ile:  neg Lys:  + Met:  neg Phe:  w Pro:  w Ser:  + Thr:  neg Trp:  + Val:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  Sens
    penicillin:  SensRNG: (0.125-0.25)
    piper-taz:  RNG: (1/4)
    meropenem:  SensRNG: (0.03-0.125)
    cefoxitin:  S(2)
    kanamycin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  Res
    metronidazole:  SensRNG: (0.06-0.5)
    clindamycin:  SensRNG: (0.25-0.5)

    References

    SPECIFIC REFERENCES FOR CLOACIBACILLUS EVRYENSIS
  • Domingo2015 - Cloacibacillus sp., a Potential Human Pathogen Associated with Bacteremia in Quebec and New Brunswick.
  • Ganesan2008 - Cloacibacillus evryensis gen. nov., sp. nov., a novel asaccharolytic, mesophilic, amino-acid-degrading bacterium within the phylum 'Synergistetes', isolated from an anaerobic sludge digester.
  • Yu2015 - Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CLOACIBACILLUS EVRYENSIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Minerbi2019 - Altered microbiome composition in individuals with fibromyalgia
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • Added: April 08, 2021